ticlopidine has been researched along with Disease Exacerbation in 45 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 7.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis." | 7.83 | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. ( Ensminger, SM; Gebhardt, J; Heim, C; Jacobi, J; Ramsperger-Gleixner, M; Weyand, M, 2016) |
| "It was previously shown that the combination of clopidogrel and everolimus reduced the development of transplant arteriosclerosis." | 7.81 | Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. ( Eckl, S; Ensminger, SM; Goldmann, K; Heim, C; Koch, N; Preidl, R; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M, 2015) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "While acute myocardial infarction (MI) is associated with impaired clopidogrel responsiveness, systematic evaluation is lacking due to the inability of functional aggregation-based assays to analyse clopidogrel responsiveness in the presence of glycoprotein IIb/IIIa inhibitors." | 7.77 | Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. ( Bauersachs, J; Flierl, U; Kobsar, A; Kössler, J; Schäfer, A; Seydelmann, N; Störk, S, 2011) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 7.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 7.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| " Ticagrelor, a potent, reversibly binding P2Y12 receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction." | 5.22 | Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2016) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists." | 4.82 | Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 3.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis." | 3.83 | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. ( Ensminger, SM; Gebhardt, J; Heim, C; Jacobi, J; Ramsperger-Gleixner, M; Weyand, M, 2016) |
| "It was previously shown that the combination of clopidogrel and everolimus reduced the development of transplant arteriosclerosis." | 3.81 | Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts. ( Eckl, S; Ensminger, SM; Goldmann, K; Heim, C; Koch, N; Preidl, R; Ramsperger-Gleixner, M; Spriewald, BM; Weyand, M, 2015) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "To determine if there is a difference in clinical outcomes among non-muscle-invasive bladder cancer patients taking fibrin clot-inhibiting (FCI) medications (aspirin, clopidogrel, or warfarin) while receiving Bacillus Calmette-Guérin (BCG) therapy compared with their counterparts not taking anticoagulation." | 3.79 | The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer. ( Badalato, GM; Hruby, GW; Lipsky, MJ; McKiernan, JM; Motamedinia, P, 2013) |
| "While acute myocardial infarction (MI) is associated with impaired clopidogrel responsiveness, systematic evaluation is lacking due to the inability of functional aggregation-based assays to analyse clopidogrel responsiveness in the presence of glycoprotein IIb/IIIa inhibitors." | 3.77 | Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. ( Bauersachs, J; Flierl, U; Kobsar, A; Kössler, J; Schäfer, A; Seydelmann, N; Störk, S, 2011) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 3.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)." | 3.73 | Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006) |
| "The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA)." | 2.84 | Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack. ( Lu, M, 2017) |
| "The treatment with Valsartan combined with Clopidogrel and Leflunomide can reduce the urinary proteins loss and renal function deterioration for IgA nephropathy patients and cause minimal adverse reactions." | 2.80 | Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. ( Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015) |
| "Aspirin has been associated with adverse heart failure outcomes, probably because of a blunting interaction with angiotensin-converting enzyme (ACE) inhibitors." | 2.72 | Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. ( Jug, B; Keber, I; Sabovic, M; Sebestjen, M, 2006) |
| "All patients with intracranial hemorrhage on initial CT with prehospital CAP therapy were included." | 1.40 | Repeat head computed tomography in anticoagulated traumatic brain injury patients: still warranted. ( Aziz, H; Friese, RS; Joseph, B; Kulvatunyou, N; O'Keeffe, T; Pandit, V; Rhee, P; Sadoun, M; Tang, A; Wynne, JL, 2014) |
| "Onyx HD-500 is a liquid embolic used to treat intracranial aneurysms." | 1.39 | Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment. ( Alaraj, A; Aletich, VA; Amin-Hanjani, S; Carlson, AP; Charbel, FT, 2013) |
| "We studied 103 patients with MCA stenosis using transcranial Doppler (TCD) and re-evaluated the TCD results at 6 months after the initial investigation and measured platelet aggregability for adenosine diphosphate (ADP) or arachidonic acid (AA)." | 1.35 | Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy. ( Cha, JK; Jeon, HW, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.44) | 18.2507 |
| 2000's | 18 (40.00) | 29.6817 |
| 2010's | 25 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinsella, JA | 1 |
| Oliver Tobin, W | 1 |
| Tierney, S | 1 |
| Feeley, TM | 1 |
| Egan, B | 1 |
| Coughlan, T | 1 |
| Ronan Collins, D | 1 |
| O'Neill, D | 1 |
| Harbison, JA | 1 |
| Doherty, CP | 1 |
| Madhavan, P | 1 |
| Moore, DJ | 1 |
| O'Neill, SM | 1 |
| Colgan, MP | 1 |
| Saqqur, M | 1 |
| Murphy, RP | 1 |
| Moran, N | 1 |
| Hamilton, G | 1 |
| McCabe, DJH | 1 |
| Lu, M | 1 |
| Ikeda-Sakai, Y | 1 |
| Sasaki, M | 1 |
| Nakase, T | 1 |
| Lin, J | 1 |
| Han, Z | 1 |
| Wang, C | 3 |
| Yi, X | 1 |
| Chai, Z | 1 |
| Zhou, Q | 1 |
| Huang, R | 1 |
| Lipsky, MJ | 1 |
| Badalato, GM | 1 |
| Motamedinia, P | 1 |
| Hruby, GW | 1 |
| McKiernan, JM | 1 |
| Joseph, B | 1 |
| Sadoun, M | 1 |
| Aziz, H | 1 |
| Tang, A | 1 |
| Wynne, JL | 1 |
| Pandit, V | 1 |
| Kulvatunyou, N | 1 |
| O'Keeffe, T | 1 |
| Friese, RS | 1 |
| Rhee, P | 1 |
| Heim, C | 2 |
| Eckl, S | 1 |
| Preidl, R | 1 |
| Ramsperger-Gleixner, M | 2 |
| Koch, N | 1 |
| Goldmann, K | 1 |
| Spriewald, BM | 1 |
| Weyand, M | 2 |
| Ensminger, SM | 2 |
| Une, D | 1 |
| Al-Atassi, T | 1 |
| Kulik, A | 1 |
| Voisine, P | 1 |
| Le May, M | 1 |
| Ruel, M | 1 |
| Cheng, G | 1 |
| Liu, D | 1 |
| Margetts, P | 1 |
| Liu, L | 2 |
| Zhao, Z | 1 |
| Liu, Z | 1 |
| Tang, L | 1 |
| Fang, Y | 1 |
| Li, H | 2 |
| Guo, Y | 1 |
| Chen, F | 1 |
| Liu, F | 1 |
| Nishimiya, K | 1 |
| Matsumoto, Y | 1 |
| Uzuka, H | 1 |
| Oyama, K | 1 |
| Tanaka, A | 1 |
| Taruya, A | 1 |
| Ogata, T | 1 |
| Hirano, M | 1 |
| Shindo, T | 1 |
| Hanawa, K | 1 |
| Hasebe, Y | 1 |
| Hao, K | 1 |
| Tsuburaya, R | 1 |
| Takahashi, J | 1 |
| Miyata, S | 1 |
| Ito, K | 1 |
| Akasaka, T | 1 |
| Shimokawa, H | 1 |
| Gebhardt, J | 1 |
| Jacobi, J | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Li, Z | 1 |
| Wang, Y | 2 |
| Zhao, X | 1 |
| Wang, D | 1 |
| Meng, X | 1 |
| Pan, Y | 1 |
| Wang, X | 1 |
| Yang, X | 1 |
| Zhang, C | 1 |
| Jing, J | 1 |
| Xian, Y | 1 |
| Johnston, SC | 1 |
| Berger, JS | 1 |
| Katona, BG | 1 |
| Jones, WS | 1 |
| Patel, MR | 1 |
| Norgren, L | 1 |
| Baumgartner, I | 1 |
| Blomster, J | 1 |
| Mahaffey, KW | 1 |
| Held, P | 1 |
| Millegård, M | 1 |
| Heizer, G | 1 |
| Reist, C | 1 |
| Fowkes, FG | 1 |
| Hiatt, WR | 1 |
| Brar, SS | 1 |
| Kim, J | 1 |
| Brar, SK | 1 |
| Zadegan, R | 1 |
| Ree, M | 1 |
| Liu, IL | 1 |
| Mansukhani, P | 1 |
| Aharonian, V | 1 |
| Hyett, R | 1 |
| Shen, AY | 1 |
| Choi, SH | 1 |
| Prasad, A | 1 |
| Tsimikas, S | 1 |
| Alberts, MJ | 2 |
| Naidech, AM | 1 |
| Bendok, BR | 1 |
| Garg, RK | 1 |
| Bernstein, RA | 1 |
| Bleck, TP | 1 |
| Batjer, HH | 1 |
| Lønborg, J | 1 |
| Kelbaek, H | 1 |
| Vejlstrup, N | 1 |
| Jørgensen, E | 1 |
| Helqvist, S | 1 |
| Saunamäki, K | 1 |
| Clemmensen, P | 1 |
| Holmvang, L | 1 |
| Treiman, M | 1 |
| Jensen, JS | 1 |
| Engstrøm, T | 1 |
| Poredos, P | 1 |
| Jezovnik, MK | 1 |
| Weise, J | 1 |
| Reinhöfer, M | 1 |
| Witte, OW | 1 |
| Mayer, TE | 1 |
| Ahn, CM | 1 |
| Hong, SJ | 1 |
| Park, JH | 1 |
| Kim, JS | 2 |
| Lim, DS | 1 |
| Masumura, Y | 1 |
| Ueda, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Schäfer, A | 1 |
| Flierl, U | 1 |
| Kössler, J | 1 |
| Seydelmann, N | 1 |
| Kobsar, A | 1 |
| Störk, S | 1 |
| Bauersachs, J | 1 |
| Kwon, SU | 1 |
| Hong, KS | 1 |
| Kang, DW | 1 |
| Park, JM | 1 |
| Lee, JH | 1 |
| Cho, YJ | 1 |
| Yu, KH | 1 |
| Koo, JS | 1 |
| Wong, KS | 1 |
| Lee, SH | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Jeong, SW | 1 |
| Bae, HJ | 1 |
| Lee, BC | 1 |
| Han, MK | 1 |
| Rha, JH | 1 |
| Kim, HY | 1 |
| Mok, VC | 1 |
| Lee, YS | 1 |
| Kim, GM | 1 |
| Suwanwela, NC | 1 |
| Yun, SC | 1 |
| Nah, HW | 1 |
| Vinod, J | 1 |
| Vadada, D | 1 |
| Korelitz, BI | 1 |
| Sonpal, N | 1 |
| Panagopoulos, G | 1 |
| Baiocco, P | 1 |
| Greenhill, C | 1 |
| Gu, DQ | 1 |
| Zhang, X | 1 |
| Luo, B | 1 |
| Long, XA | 1 |
| Duan, CZ | 1 |
| Carlson, AP | 1 |
| Alaraj, A | 1 |
| Amin-Hanjani, S | 1 |
| Charbel, FT | 1 |
| Aletich, VA | 1 |
| Yang, CW | 1 |
| Chen, YC | 1 |
| Dunn, P | 1 |
| Chang, MY | 1 |
| Fang, JT | 1 |
| Huang, CC | 1 |
| Payne, DA | 1 |
| Jones, CI | 1 |
| Hayes, PD | 1 |
| Thompson, MM | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Goodall, AH | 1 |
| Naylor, AR | 1 |
| Rioufol, G | 1 |
| Gilard, M | 1 |
| Finet, G | 1 |
| Ginon, I | 1 |
| Boschat, J | 1 |
| André-Fouët, X | 1 |
| Skvortsova, VI | 1 |
| Shamalov, NA | 1 |
| Phillips, DR | 1 |
| Conley, PB | 1 |
| Sinha, U | 1 |
| Andre, P | 1 |
| Ishikawa, T | 1 |
| Mutoh, M | 1 |
| Fuda, Y | 1 |
| Sakamoto, H | 1 |
| Okada, H | 1 |
| Higashitani, M | 1 |
| Nakano, Y | 1 |
| Yamaguchi, J | 1 |
| Enta, K | 1 |
| Satoh, T | 1 |
| Imai, K | 1 |
| Horie, T | 1 |
| Mochizuki, S | 1 |
| Jug, B | 1 |
| Sebestjen, M | 1 |
| Sabovic, M | 1 |
| Keber, I | 1 |
| Jeon, HW | 1 |
| Cha, JK | 1 |
| Satish, B | 1 |
| Tressa, K | 1 |
| Harish, CR | 1 |
| Schulz, C | 1 |
| Konrad, I | 1 |
| Sauer, S | 1 |
| Orschiedt, L | 1 |
| Koellnberger, M | 1 |
| Lorenz, R | 1 |
| Walter, U | 1 |
| Massberg, S | 1 |
| Kirichenko, AA | 1 |
| Mantserova, OA | 1 |
| Lebedeva, AIu | 1 |
| D'iachkova, NV | 1 |
| Voloshina, NM | 1 |
| Mazurov, VI | 1 |
| Nifontov, VM | 1 |
| Tyrenko, VV | 1 |
| Kolina, IG | 1 |
| Cherkashina, AL | 1 |
| Shkodina, NV | 1 |
| Mazalov, KV | 1 |
| Spiropulos, NA | 1 |
| Eremenko, IA | 1 |
| Kuzin, AI | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Tanaka, T | 1 |
| Takei, M | 1 |
| Fukuta, Y | 1 |
| Higashino, R | 1 |
| Fukuda, Y | 1 |
| Nomura, Y | 1 |
| Ito, S | 1 |
| Tamaki, H | 1 |
| Kurimoto, T | 1 |
| Suzuki, Y | 1 |
| Wilson, JM | 1 |
| Ferguson, JJ | 1 |
| Horwich, TB | 1 |
| Fonarow, GC | 1 |
| Morino, Y | 1 |
| Limpijankit, T | 1 |
| Honda, Y | 1 |
| Lansky, AJ | 1 |
| Waksman, R | 1 |
| Bonneau, HN | 1 |
| Yock, PG | 1 |
| Mintz, GS | 1 |
| Fitzgerald, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Effect of Conditioning on Myocardial Damage in ST-elevation Myocardial Infarction - Comparison of Combined Intrahospital Preconditioning Plus Postconditioning Versus Postconditioning Versus Control.[NCT02158468] | 600 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Postconditioning Used to Limit Final Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction[NCT00507156] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039] | Phase 4 | 457 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| the Treatment of Intracranial Aneurysm Using Different Types of Stents Assisted Embolization :Trials of Clinical Curative Effect, Follow-up Study and Hemodynamics[NCT03387995] | 2,000 participants (Anticipated) | Observational | 2016-09-01 | Active, not recruiting | |||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | pariticipants (Number) |
|---|---|
| Cilostazol | 34 |
| Clopidogrel | 23 |
including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 15 |
| Clopidogrel | 10 |
"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 20 |
| Clopidogrel | 32 |
including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 11 |
| Clopidogrel | 7 |
ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 9 |
| Clopidogrel | 5 |
life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | events (Number) |
|---|---|
| Cilostazol | 2 |
| Clopidogrel | 6 |
4 reviews available for ticlopidine and Disease Exacerbation
| Article | Year |
|---|---|
Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease Progression; Dose-Respo | 2010 |
Therapeutic approaches in arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl | 2005 |
Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Topics: Animals; Arteriosclerosis; Aspirin; Disease Progression; Endothelium, Vascular; Humans; Platelet Act | 1999 |
Prevention of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2002 |
14 trials available for ticlopidine and Disease Exacerbation
| Article | Year |
|---|---|
Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Chi-Square Distribution; China; Cl | 2017 |
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease | 2015 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middl | 2016 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Di | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou | 2011 |
Thrombotic thrombocytopenic purpura (TTP): initial treatment with plasma exchange plus steroids and immunosuppressive agents for relapsing cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Bilirubin; Biomarkers; Combined Modal | 2003 |
Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Progression; Drug Therapy, Combination; Endar | 2004 |
[The results of the MATCH study evidence for advantages of Clopidogrel monotherapy as secondary prophylaxis in cerebrovascular pathology].
Topics: Aged; Brain Ischemia; Clopidogrel; Disease Progression; Double-Blind Method; Female; Follow-Up Studi | 2004 |
Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Output, Low; Clopidogrel; Cross-Over Studies; Disease Prog | 2006 |
[Unstable angina: efficacy and tolerability of therapy with aspirin and aspirin combined with ticlopidine].
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Drug Therap | 2007 |
Late vascular response to repeat stenting for in-stent restenosis with and without radiation: an intravascular ultrasound volumetric analysis.
Topics: Blood Vessel Prosthesis Implantation; Brachytherapy; Cohort Studies; Coronary Restenosis; Disease Pr | 2002 |
27 other studies available for ticlopidine and Disease Exacerbation
| Article | Year |
|---|---|
Assessment of 'on-treatment platelet reactivity' and relationship with cerebral micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
Topics: Aged; Aspirin; Brain; Carotid Stenosis; Case-Control Studies; Clopidogrel; Disease Progression; Fema | 2017 |
Effects With and Without Clopidogrel Loading Treatment for Acute Ischemic Cerebrovascular Disease Patients: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Brain; Brain Ischemia; Clinical Decision-Making; Clopidogrel; Disease Progr | 2017 |
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto | 2018 |
The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Anticoagulants; Aspirin; BCG Vaccine; Clopidogrel; | 2013 |
Repeat head computed tomography in anticoagulated traumatic brain injury patients: still warranted.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Injuries; Clopidogrel; Cohort Studies | 2014 |
Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts.
Topics: Allografts; Animals; Aorta; Arteriosclerosis; Clopidogrel; Disease Progression; Everolimus; Immunity | 2015 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vess | 2015 |
Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Biomarkers; Chemokine | 2016 |
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; F | 2008 |
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; H | 2008 |
CHARISMA revisited: is the glass half full or just empty?
Topics: Aspirin; Clopidogrel; Coronary Disease; Disease Progression; Humans; Platelet Aggregation Inhibitors | 2008 |
Reduced platelet activity is associated with more intraventricular hemorrhage.
Topics: Adult; Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Cerebral Hemorrhage; Clopidogrel; C | 2009 |
Early stent thrombosis with progressive brainstem infarction in a clopidogrel non-responder.
Topics: Aged; Brain Infarction; Brain Ischemia; Clopidogrel; Disease Progression; Humans; Magnetic Resonance | 2010 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction.
Topics: Aged; Clopidogrel; Disease Progression; Drug Resistance; Early Diagnosis; Female; Flow Cytometry; Hu | 2011 |
The effect of antiplatelet therapy in patients with inflammatory bowel disease.
Topics: Aspirin; Clopidogrel; Disease Progression; Female; Humans; Inflammatory Bowel Diseases; Male; Platel | 2012 |
Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?
Topics: Animals; Carcinoma, Hepatocellular; Chemoprevention; Clopidogrel; Disease Models, Animal; Disease Pr | 2012 |
The effect of Neuroform stent-assisted coil embolization of wide-necked intracranial aneurysms and clinical factors on progressive aneurysm occlusion on angiographic follow-up.
Topics: Adult; Aspirin; Cerebral Angiography; Clopidogrel; Disease Progression; Embolization, Therapeutic; F | 2013 |
Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment.
Topics: Angioplasty; Aspirin; Carotid Artery Diseases; Carotid Stenosis; Clopidogrel; Constriction, Patholog | 2013 |
Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Follow | 2004 |
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno | 2006 |
Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; D | 2008 |
Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Disease Progression; Drug H | 2007 |
Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta; Apolipoproteins E; Aspirin; Atherosclerosis; Blood Platelets; Carotid Arteries; Chol | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease.
Topics: Animals; Arachidonic Acid; Aspirin; Disease Models, Animal; Disease Progression; Drug Evaluation, Pr | 1999 |